![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Schmidt H. Woodcock B.G. Geisslinger G.
Publisher: Adis International
ISSN: 0114-5916
Source: Drug Safety, Vol.27, Iss.3, 2004-01, pp. : 185-196
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer
Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Benefit-Risk Assessment of Levetiracetam in the Treatment of Partial Seizures
Drug Safety, Vol. 28, Iss. 10, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis
By Mikuls T.R.
Drug Safety, Vol. 26, Iss. 1, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)